Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $262.6 million.

  • Ani Pharmaceuticals' Cash & Current Investments rose 81.11% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.2 million, marking a year-over-year decrease of 7.14%. This contributed to the annual value of $144.9 million for FY2024, which is 34.47% down from last year.
  • Ani Pharmaceuticals' Cash & Current Investments amounted to $262.6 million in Q3 2025, which was up 20.57% from $217.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Cash & Current Investments registered a high of $262.6 million during Q3 2025, and its lowest value of $15.3 million during Q3 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Cash & Current Investments value was $193.1 million (recorded in 2023), while the average stood at $184.8 million.
  • In the last 5 years, Ani Pharmaceuticals' Cash & Current Investments soared by 718.38% in 2021 and then crashed by 49.45% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $105.3 million in 2021, then plummeted by 49.45% to $53.2 million in 2022, then soared by 315.38% to $221.1 million in 2023, then tumbled by 34.47% to $144.9 million in 2024, then spiked by 81.11% to $262.6 million in 2025.
  • Its last three reported values are $262.6 million in Q3 2025, $217.8 million for Q2 2025, and $149.8 million during Q1 2025.